Rubius Therapeutics Strengthens Leadership Team with Appointment of Andrew Oh as Chief Financial Officer

CAMBRIDGE, Mass.--December 14, 2017--Rubius Therapeutics, a biotechnology company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, today announced the appointment of Andrew Oh as Chief Financial Officer. Mr. Oh brings to Rubius more than 20 years of experience in finance and the biopharmaceutical industry.

Prior to joining Rubius, Mr. Oh served as Chief Investment Officer and Chief Operating Officer at Leerink Pharmaceutical Investments, a subsidiary of Leerink Capital Partners. Prior to Leerink, Mr. Oh was a senior analyst covering global pharmaceutical companies and was a portfolio manager at Fidelity Investments for seven years. Mr. Oh managed the Fidelity Select Pharmaceuticals Portfolio fund which was rated by Lipper as the number one global health/biotechnology fund based on three and five year performance. He received a B.A. in Biology from Washington University in St. Louis and holds a MBA from Northwestern’s Kellogg School of Management.

“Andrew’s career-long experience as an investor and analyst at some of the best financial institutions, coupled with his extensive network in the global biopharmaceutical community make him an excellent addition to the Rubius team as the company continues to grow and work to advance the next generation of cellular therapies,” said Torben Straight Nissen, Ph.D., President of Rubius Therapeutics.

“Rubius is one of the most exciting biotech companies I have seen in my investing career and has the potential to transform care for people suffering from a broad range of serious diseases,” said Mr. Oh. “I am honored to be part of a team dedicated to pioneering the next generation of cellular therapies and the development of breakthrough therapies for patients in need.”

About Rubius Therapeutics

Rubius Therapeutics, a 2017 “Fierce 15” award winner, is creating RCTs™ as a new class of medicines. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. The company was conceived and launched by Flagship VentureLabs®, the innovation foundry where a team of scientific entrepreneurs systematically evolve enterprising ideas based upon previously undiscovered areas of science into real-world inventions and ventures. Rubius® was founded by Flagship Pioneering in 2014. For more information please visit www.rubiustx.com.

About RCT™ Products

RCT™ products are genetically engineered, enucleated red cells that are being developed to provide allogeneic, ready-to-use cellular therapies to patients across multiple therapeutic areas. The advantages of RCT products over other therapies include immuno-privileged presentation of proteins within or on the red cell, high target avidity and affinity, and long circulation half-life. Rubius RCTs exhibit fundamentally unique and potent biology; that have been engineered to replace missing enzymes for patients living with a variety of rare diseases, to kill tumors, and to upregulate or downregulate the immune system to treat both cancer and autoimmune disorders.